Damora Therapeutics, Inc. GLTO
Set alert
21.58 USD 0.00 0.00%
As of Jun 4, 12:02 PM ET
21.58 Day range 23.54
4.40 52-week range 23.50
- YTD
- -6.21%
- 1 year
- +659.86%
- Open
- 22.26
- Prev close
- 21.58
- Mkt cap
- 6.22M
- Vol
- 609
- Avg vol
- 26.14K
- EPS
- -19.11
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 21.58
- High
- 23.54
- Forward P/E
- -0.25
- Beta
- 1.25
- Short ratio
- 1.08
- Inst. own
- 12.03%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 6.25
- 200-d avg
- 12.56
- 1y target
- 10.00
2Y chart
Events in this range
- Jun 10, 2024Rating: Oppenheimer · Outperform → Outperform
- Aug 30, 2024Split: 1 for 25
- Oct 17, 2024Rating: Oppenheimer · Outperform → Outperform
Signals (93)
| Name | Date | Ago |
|---|---|---|
| SMA: Bearish | Mar 10, 2026 | 7 months ago |
| MACD: Sell Signal | Mar 3, 2026 | 8 months ago |
| SMA: Bullish | Feb 12, 2026 | 8 months ago |
| MACD: Buy Signal | Feb 12, 2026 | 8 months ago |
| SMA: Bearish | Feb 9, 2026 | 8 months ago |
| SMA: Bullish | Feb 6, 2026 | 8 months ago |
| SMA: Bearish | Feb 4, 2026 | 8 months ago |
| MACD: Sell Signal | Feb 4, 2026 | 8 months ago |
| MACD: Buy Signal | Feb 2, 2026 | 9 months ago |
| MACD: Sell Signal | Jan 28, 2026 | 9 months ago |
| MACD: Buy Signal | Jan 20, 2026 | 9 months ago |
| SMA: Bullish | Jan 12, 2026 | 9 months ago |
| SMA: Bearish | Jan 8, 2026 | 9 months ago |
| RSI: Overbought | Dec 26, 2025 | 10 months ago |
| MACD: Sell Signal | Dec 18, 2025 | 10 months ago |
| RSI: Overbought | Dec 9, 2025 | 10 months ago |
| MACD: Buy Signal | Dec 5, 2025 | 11 months ago |
| RSI: Overbought | Dec 5, 2025 | 11 months ago |
| MACD: Sell Signal | Nov 24, 2025 | 11 months ago |
| SMA: Bullish | Nov 10, 2025 | 11 months ago |
| MACD: Buy Signal | Nov 10, 2025 | 11 months ago |
| RSI: Overbought | Nov 10, 2025 | 11 months ago |
| SMA: Bearish | Nov 4, 2025 | 12 months ago |
| MACD: Sell Signal | Oct 20, 2025 | 1 year ago |
| SMA: Bullish | Oct 7, 2025 | 1 year ago |
| RSI: Overbought | Oct 7, 2025 | 1 year ago |
| SMA: Bearish | Oct 6, 2025 | 1 year ago |
| SMA: Bullish | Oct 2, 2025 | 1 year ago |
| SMA: Bearish | Sep 30, 2025 | 1 year ago |
| SMA: Bullish | Sep 23, 2025 | 1 year ago |
| SMA: Bullish | Sep 23, 2025 | 1 year ago |
| RSI: Overbought | Sep 23, 2025 | 1 year ago |
| MACD: Buy Signal | Sep 22, 2025 | 1 year ago |
| RSI: Oversold | Sep 9, 2025 | 1 year ago |
| RSI: Oversold | Sep 3, 2025 | 1 year ago |
| MACD: Sell Signal | Aug 28, 2025 | 1 year ago |
| MACD: Buy Signal | Aug 25, 2025 | 1 year ago |
| SMA: Bearish | Jul 30, 2025 | 1 year ago |
| MACD: Sell Signal | Jul 29, 2025 | 1 year ago |
| MACD: Buy Signal | Jul 14, 2025 | 1 year ago |
| RSI: Overbought | Jul 14, 2025 | 1 year ago |
| MACD: Sell Signal | Jul 7, 2025 | 1 year ago |
| MACD: Buy Signal | Jul 2, 2025 | 1 year ago |
| MACD: Sell Signal | Jun 30, 2025 | 1 year ago |
| SMA: Bullish | May 29, 2025 | 1 year ago |
| MACD: Buy Signal | Apr 21, 2025 | 1 year ago |
| MACD: Sell Signal | Mar 27, 2025 | 1 year ago |
| SMA: Bearish | Mar 26, 2025 | 1 year ago |
| SMA: Bullish | Mar 21, 2025 | 1 year ago |
| RSI: Overbought | Mar 21, 2025 | 1 year ago |
| MACD: Buy Signal | Mar 17, 2025 | 1 year ago |
| MACD: Sell Signal | Feb 24, 2025 | 1 year ago |
| MACD: Buy Signal | Feb 19, 2025 | 1 year ago |
| MACD: Sell Signal | Jan 31, 2025 | 1 year ago |
| SMA: Bearish | Jan 27, 2025 | 1 year ago |
| SMA: Bullish | Jan 24, 2025 | 1 year ago |
| SMA: Bearish | Jan 22, 2025 | 1 year ago |
| SMA: Bullish | Jan 21, 2025 | 1 year ago |
| MACD: Buy Signal | Jan 17, 2025 | 1 year ago |
| MACD: Sell Signal | Jan 16, 2025 | 1 year ago |
| MACD: Buy Signal | Dec 24, 2024 | 1 year ago |
| MACD: Sell Signal | Dec 19, 2024 | 1 year ago |
| RSI: Oversold | Dec 18, 2024 | 1 year ago |
| RSI: Oversold | Dec 13, 2024 | 1 year ago |
| MACD: Buy Signal | Dec 2, 2024 | 1 year ago |
| MACD: Sell Signal | Nov 22, 2024 | 1 year ago |
| RSI: Oversold | Nov 18, 2024 | 1 year ago |
| MACD: Buy Signal | Oct 24, 2024 | 2 years ago |
| RSI: Oversold | Oct 7, 2024 | 2 years ago |
| MACD: Sell Signal | Sep 24, 2024 | 2 years ago |
| SMA: Bearish | Sep 20, 2024 | 2 years ago |
| SMA: Bullish | Sep 17, 2024 | 2 years ago |
| SMA: Bearish | Sep 13, 2024 | 2 years ago |
| SMA: Bullish | Sep 12, 2024 | 2 years ago |
| MACD: Buy Signal | Sep 12, 2024 | 2 years ago |
| SMA: Bearish | Aug 28, 2024 | 2 years ago |
| MACD: Sell Signal | Aug 28, 2024 | 2 years ago |
| MACD: Buy Signal | Aug 14, 2024 | 2 years ago |
| SMA: Bullish | Aug 13, 2024 | 2 years ago |
| SMA: Bearish | Aug 2, 2024 | 2 years ago |
| MACD: Sell Signal | Aug 2, 2024 | 2 years ago |
| SMA: Bullish | Jul 24, 2024 | 2 years ago |
| SMA: Bearish | Jul 19, 2024 | 2 years ago |
| SMA: Bullish | Jul 18, 2024 | 2 years ago |
| SMA: Bearish | Jul 16, 2024 | 2 years ago |
| SMA: Bullish | Jul 15, 2024 | 2 years ago |
| MACD: Buy Signal | Jul 3, 2024 | 2 years ago |
| MACD: Sell Signal | Jul 2, 2024 | 2 years ago |
| MACD: Buy Signal | Jun 24, 2024 | 2 years ago |
| RSI: Oversold | Jun 18, 2024 | 2 years ago |
| RSI: Oversold | Jun 6, 2024 | 2 years ago |
| RSI: Oversold | Jun 4, 2024 | 2 years ago |
| MACD: Sell Signal | May 15, 2024 | 2 years ago |
Key statistics
- Market cap
- 6.22M
- Enterprise value
- -13.46M
- Trailing P/E
- 0.00
- Forward P/E
- -0.25
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.28
- EPS (TTM)
- -19.11
- Beta
- 1.25
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -16.52M
- Total cash
- 19.68M
- Total debt
- 32.00K
- Return on equity
- -72.61%
- Shares outstanding
- 1.32M
- Short % of float
- 1.59%
- 50-day average
- 6.25
- 200-day average
- 12.56
Analyst view
Consensus: none
Price target (mean) 10.00
Ratings (0m) 1 1 buy · 0 hold · 0 sell
- Strong buy0
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -2.82.
Financials — quick view
GLTO Revenue — quarterly 0
GLTO Net income — quarterly -3.13M
GLTO EPS — quarterly -2.36
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 17, 2024 | Oppenheimer | main | Outperform | Outperform |
| Jun 10, 2024 | Oppenheimer | main | Outperform | Outperform |
| Sep 28, 2023 | HC Wainwright & Co. | down | Buy | Neutral |
| Aug 21, 2023 | HC Wainwright & Co. | main | Buy | Buy |
| Aug 15, 2023 | SVB Leerink | down | Outperform | Market Perform |
| Aug 1, 2023 | Oppenheimer | reit | Outperform | Outperform |
About Damora Therapeutics, Inc.
Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Denmark
- Website
- galecto.com
News
- What Makes Galecto, Inc. (DMRA) a Strong Momentum Stock: Buy Now?
- Galecto, Inc. (NASDAQ:GLTO) Given Consensus Recommendation of “Moderate Buy” by Brokerages
- Galecto, Inc. (NASDAQ:GLTO) Short Interest Up 86.6% in February
- Galecto Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $316.3 Million
- 12 Health Care Stocks Moving In Thursday's Intraday Session
- 12 Health Care Stocks Moving In Wednesday's After-Market Session
- Galecto Announces Pricing of $275 Million Underwritten Public Offering
- Galecto, Inc. (NASDAQ:GLTO) Given Average Rating of “Moderate Buy” by Analysts
- Analysts Set Galecto, Inc. (NASDAQ:GLTO) PT at $41.00
- Comparing Galecto (NASDAQ:GLTO) and Avidity Biosciences (NASDAQ:RNA)
Your note
Sign in to keep a note on GLTO — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CHRISTGAU STEPHAN | Director | Purchase | Nov 1, 2020 | 0 |
| FREVE JONATHAN | Chief Financial Officer | Purchase | Dec 2, 2021 | 12,000 |
| KHUONG CHAU QUANG | Director and Beneficial Owner of more than 10% of a Class of Security | Purchase | Nov 1, 2020 | 0 |
| LINDMARK BERTIL | Officer | Purchase | Mar 21, 2022 | 16,604 |
| MUNSHI AMIT D | Director | Conversion of Exercise of derivative security | Nov 1, 2020 | 4,793 |
| NOVO HOLDINGS A/S | Beneficial Owner of more than 10% of a Class of Security | Purchase | Nov 1, 2020 | 2,497,790 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Novo Holdings A/S | 7.59% | 99,913 | 471.66K | Sep 29, 2024 |
| Renaissance Technologies, LLC | 1.62% | 21,382 | 100.94K | Sep 29, 2024 |
| UBS Group AG | 0.39% | 5,099 | 24.07K | Sep 29, 2024 |
| Bank of America Corporation | 0.09% | 1,225 | 5.78K | Sep 29, 2024 |
| Blackrock Inc. | 0.04% | 490 | 2.31K | Sep 29, 2024 |
| Tower Research Capital LLC (TRC) | 0.03% | 346 | 1.63K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Extended Market Index Fund | 0.65% | 8,508 | 40.16K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.34% | 4,541 | 21.44K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.19% | 2,453 | 11.58K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.09% | 1,190 | 5.62K | Oct 30, 2024 |
| Fidelity NASDAQ Composite Index Fund | 0.04% | 469 | 2.21K | Oct 30, 2024 |